Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 135.10K | 139.80K | 164.90K | 155.00K | 216.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 135.10K | 139.80K | 164.90K | 155.00K | 216.50K |
| Cost of Revenue | 41.40K | 24.80K | 80.30K | 51.90K | 73.00K |
| Gross Profit | 93.70K | 115.00K | 84.60K | 103.10K | 143.50K |
| SG&A Expenses | 234.00K | 280.70K | 266.90K | 501.80K | 1.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 275.40K | 305.60K | 347.20K | 553.70K | 1.24M |
| Operating Income | -140.20K | -165.80K | -182.30K | -398.70K | -1.02M |
| Income Before Tax | -243.10K | -278.50K | -279.20K | -592.60K | 3.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -243.10K | -278.50K | -279.20K | -592.60K | 3.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -243.10K | -278.50K | -279.20K | -592.60K | 3.23M |
| EBIT | -140.20K | -165.80K | -182.30K | -398.70K | -1.02M |
| EBITDA | -138.40K | -160.30K | -176.90K | -393.20K | -1.02M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 7.62B | 7.61B | 7.60B | 7.60B | 7.60B |
| Average Diluted Shares Outstanding | 7.62B | 7.61B | 7.60B | 7.60B | 31.07B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |